BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1155 related articles for article (PubMed ID: 33939694)

  • 1. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
    Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
    Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
    Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
    [No Abstract]   [Full Text] [Related]  

  • 3. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-hepatectomy dynamic circulating tumor DNA to predict pathologic response to preoperative chemotherapy and post-hepatectomy recurrence in patients with colorectal liver metastases.
    Liu M; Bao Q; Zhao T; Huang L; Zhang D; Wang Y; Yan X; Wang H; Jin K; Liu W; Wang K; Xing B
    Hepatol Int; 2024 Jun; 18(3):1029-1039. PubMed ID: 38427145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases.
    Bolhuis K; van 't Erve I; Mijnals C; Delis-Van Diemen PM; Huiskens J; Komurcu A; Lopez-Yurda M; van den Broek D; Swijnenburg RJ; Meijer GA; Punt CJA; Fijneman RJA
    EBioMedicine; 2021 Aug; 70():103498. PubMed ID: 34333237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: a prospective cohort study.
    Li Y; Xu J; Hu X; Chen Y; Liu F; Chen Y; Ma X; Dong Q; Sun L; Mo S; Zhang L; He X; Tong S; Wu H; Li W; Cai S; Zhu S; Pan Q; Peng J
    Int J Surg; 2024 May; 110(5):2776-2787. PubMed ID: 38445460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
    Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Ann Oncol; 2019 Sep; 30(9):1472-1478. PubMed ID: 31250894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
    Øgaard N; Reinert T; Henriksen TV; Frydendahl A; Aagaard E; Ørntoft MW; Larsen MØ; Knudsen AR; Mortensen FV; Andersen CL
    Eur J Cancer; 2022 Mar; 163():163-176. PubMed ID: 35074652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer.
    Chen G; Peng J; Xiao Q; Wu HX; Wu X; Wang F; Li L; Ding P; Zhao Q; Li Y; Wang D; Shao Y; Bao H; Pan Z; Ding KF; Cai S; Wang F; Xu RH
    J Hematol Oncol; 2021 May; 14(1):80. PubMed ID: 34001194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
    Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
    Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.
    Tie J; Cohen JD; Wang Y; Li L; Christie M; Simons K; Elsaleh H; Kosmider S; Wong R; Yip D; Lee M; Tran B; Rangiah D; Burge M; Goldstein D; Singh M; Skinner I; Faragher I; Croxford M; Bampton C; Haydon A; Jones IT; S Karapetis C; Price T; Schaefer MJ; Ptak J; Dobbyn L; Silliman N; Kinde I; Tomasetti C; Papadopoulos N; Kinzler K; Volgestein B; Gibbs P
    Gut; 2019 Apr; 68(4):663-671. PubMed ID: 29420226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
    Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
    Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Preoperative Circulating Tumor DNA Status on Survival Outcomes After Hepatectomy for Resectable Colorectal Liver Metastases.
    Kobayashi S; Nakamura Y; Taniguchi H; Odegaard JI; Nomura S; Kojima M; Sugimoto M; Konishi M; Gotohda N; Takahashi S; Yoshino T
    Ann Surg Oncol; 2021 Aug; 28(8):4744-4755. PubMed ID: 33393041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
    Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
    Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
    Reinert T; Petersen LMS; Henriksen TV; Larsen MØ; Rasmussen MH; Johansen AFB; Øgaard N; Knudsen M; Nordentoft I; Vang S; Krag SRP; Knudsen AR; Mortensen FV; Andersen CL
    Int J Cancer; 2022 May; 150(9):1537-1548. PubMed ID: 34994972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
    Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
    World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
    Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
    BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
    Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T
    Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.
    Henriksen TV; Tarazona N; Frydendahl A; Reinert T; Gimeno-Valiente F; Carbonell-Asins JA; Sharma S; Renner D; Hafez D; Roda D; Huerta M; Roselló S; Madsen AH; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Sethi H; Aleshin A; Cervantes A; Andersen CL
    Clin Cancer Res; 2022 Feb; 28(3):507-517. PubMed ID: 34625408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.